1. Coverage objective
Biotech Stock Intel focuses on publicly traded biotechnology and healthcare companies and the events that can materially change how their programs are understood. Coverage may include clinical readouts, regulatory submissions and decisions, FDA advisory committee meetings, PDUFA dates, conference presentations, enrollment milestones, partnerships, commercial events, and other company-guided milestones.
Coverage is selective rather than exhaustive. A company, asset, indication, filing, or event may be absent even when it is publicly available.
2. Source hierarchy
We give the greatest weight to primary materials, including:
- regulator publications and official regulatory calendars;
- company regulatory filings, investor-relations releases, presentations, and earnings materials;
- clinical-trial registries and scientific or medical-conference materials;
- reputable news and selected third-party structured data sources.
Where a source link is available, event pages link back to it so users can review the underlying disclosure. The latest primary disclosure should control when sources conflict.
3. Event extraction and classification
Source records are converted into structured fields such as company, ticker, drug or asset, indication, development stage, event type, expected timing, and source URL. Automated ingestion and normalization are supplemented by consistency checks and selective editorial review. Similar phrases may be grouped into a common category to make filtering practical.
Classifications describe the nature of the disclosed milestone; they do not assess the probability of success. “Phase 3,” “PDUFA,” “ADCOM,” “data readout,” and similar labels should be read alongside the source because programs and regulatory pathways differ.
4. Date precision and normalization
Companies often guide to an exact date, month, quarter, half-year, year, conference window, or general period such as “mid-year.” We preserve the source’s timing language where available. A structured reference date may also be used so approximate events can appear in calendars and chronological lists.
- Exact dates represent a specifically disclosed calendar date.
- Approximate dates represent broader guidance and should not be interpreted as a promised deadline.
- To be announced or undated events may remain outside date-filtered views until timing becomes available.
All displayed dates can change. A company’s newest disclosure or the relevant regulator’s official record supersedes an earlier entry.
5. PDUFA and advisory committee events
PDUFA dates are target action dates associated with an FDA review timeline; they are not guaranteed decision dates and do not imply approval. Advisory committee dates identify scheduled public meetings or expected committee activity; committees may be rescheduled or canceled, and their votes are advisory rather than binding on the FDA.
6. Market and company information
Certain quotes, price changes, company profiles, fundamentals, analyst measures, news references, insider-transaction information, and other market information may be sourced or derived from Yahoo Finance and other third-party market-data providers. Data may be delayed, adjusted, incomplete, or unavailable and can differ across providers, exchanges, filings, and time zones.
Market information is cached on different schedules depending on the field. A displayed “updated” time indicates when our system last refreshed or assembled a page; it does not mean every underlying field was published or traded at that time. Exchange and issuer records should be used for authoritative confirmation.
7. Calculated fields and research signals
Some fields are calculations or classifications rather than directly reported facts:
- Price change and implied analyst upside/downside use available price and consensus inputs and may change when either input changes.
- Cash runway is an estimate based on available cash and burn information. Financing, milestone receipts, restructuring, working-capital changes, and non-recurring items can make actual liquidity materially different.
- Mover, suspected-mover, management-interest, hedge-fund, or similar signals are research labels used to organize information. They are not recommendations, probability forecasts, or evidence that a security will rise or fall.
- Analyst consensus and targets aggregate third-party opinions. They are estimates, can be stale, and do not represent Biotech Stock Intel’s opinion.
8. Updates, quality checks, and corrections
Information is refreshed on schedules that vary by dataset. We use automated validation, required-field checks, relationship checks, source-link validation where practical, and monitoring for synchronization failures. Select records may receive manual review, especially when timing or classification is ambiguous.
These controls reduce but do not eliminate errors. If we identify a material error, we may correct, reclassify, or remove the record. To report a possible error, email support@biotechstockintel.com with the ticker, event, disputed field, and a link to the primary source.
9. Independence and conflicts
Biotech Stock Intel is an independent research platform and is not affiliated with the companies, regulators, exchanges, Yahoo Finance, or other third-party data providers merely because their information or names appear in the Service. Third-party trademarks belong to their owners.
Unless expressly disclosed alongside particular content, inclusion, prominence, classification, or omission is not paid issuer promotion. If sponsored content, affiliate compensation, or a material financial conflict is introduced, it should be identified clearly where the content appears.
10. How to use the research
Use the Service as a discovery and organization layer. Before making a decision, open the linked source, check the issuer’s latest filings and investor-relations materials, confirm regulatory information with the relevant authority, verify current market data, and consider risks not captured by a calendar entry. Nothing in the methodology converts the Service into investment or medical advice.